JP2009534401A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009534401A5 JP2009534401A5 JP2009506711A JP2009506711A JP2009534401A5 JP 2009534401 A5 JP2009534401 A5 JP 2009534401A5 JP 2009506711 A JP2009506711 A JP 2009506711A JP 2009506711 A JP2009506711 A JP 2009506711A JP 2009534401 A5 JP2009534401 A5 JP 2009534401A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- monoclonal antibody
- concentration
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 177
- 239000000872 buffer Substances 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 48
- 239000012634 fragment Substances 0.000 claims description 35
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 30
- 229960003589 arginine hydrochloride Drugs 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 239000005557 antagonist Substances 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 25
- 230000027455 binding Effects 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 22
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 21
- 239000007979 citrate buffer Substances 0.000 claims description 21
- 229950004563 lucatumumab Drugs 0.000 claims description 21
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims description 20
- 229930182817 methionine Natural products 0.000 claims description 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 18
- 150000001413 amino acids Chemical group 0.000 claims description 18
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 18
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 18
- 229940068977 polysorbate 20 Drugs 0.000 claims description 18
- 239000004475 Arginine Substances 0.000 claims description 14
- 206010025323 Lymphomas Diseases 0.000 claims description 14
- 229960003121 arginine Drugs 0.000 claims description 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 13
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 12
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 12
- 230000002378 acidificating effect Effects 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 12
- 210000004408 hybridoma Anatomy 0.000 claims description 12
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 10
- 101150013553 CD40 gene Proteins 0.000 claims description 10
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 10
- 239000006172 buffering agent Substances 0.000 claims description 10
- 239000001509 sodium citrate Substances 0.000 claims description 10
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 208000006994 Precancerous Conditions Diseases 0.000 claims description 6
- 230000000172 allergic effect Effects 0.000 claims description 6
- 229940024606 amino acid Drugs 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 230000009137 competitive binding Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 108010063916 CD40 Antigens Proteins 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 230000003325 follicular Effects 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 4
- 201000000306 sarcoidosis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 210000001685 thyroid gland Anatomy 0.000 claims description 4
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 2
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 2
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 2
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims description 2
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 2
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 2
- 108010068370 Glutens Proteins 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 206010066476 Haematological malignancy Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims description 2
- 208000024781 Immune Complex disease Diseases 0.000 claims description 2
- 206010053574 Immunoblastic lymphoma Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims description 2
- 201000003791 MALT lymphoma Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 208000037902 enteropathy Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 235000021312 gluten Nutrition 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 208000025750 heavy chain disease Diseases 0.000 claims description 2
- 230000002949 hemolytic effect Effects 0.000 claims description 2
- 208000021173 high grade B-cell lymphoma Diseases 0.000 claims description 2
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 claims description 2
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims description 2
- 208000001875 irritant dermatitis Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims description 2
- 201000006894 monocytic leukemia Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 210000005170 neoplastic cell Anatomy 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 208000037244 polycythemia vera Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000002537 thrombolytic effect Effects 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 208000025883 type III hypersensitivity disease Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229960004452 methionine Drugs 0.000 description 11
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79401106P | 2006-04-21 | 2006-04-21 | |
| US60/794,011 | 2006-04-21 | ||
| PCT/US2007/066757 WO2007124299A2 (en) | 2006-04-21 | 2007-04-17 | Antagonist anti-cd40 antibody pharmaceutical compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013059446A Division JP2013129673A (ja) | 2006-04-21 | 2013-03-22 | 拮抗剤抗ｃｄ４０抗体薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009534401A JP2009534401A (ja) | 2009-09-24 |
| JP2009534401A5 true JP2009534401A5 (https=) | 2011-04-21 |
| JP5290152B2 JP5290152B2 (ja) | 2013-09-18 |
Family
ID=38556677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506711A Expired - Fee Related JP5290152B2 (ja) | 2006-04-21 | 2007-04-17 | 拮抗剤抗ｃｄ４０抗体薬学的組成物 |
| JP2013059446A Pending JP2013129673A (ja) | 2006-04-21 | 2013-03-22 | 拮抗剤抗ｃｄ４０抗体薬学的組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013059446A Pending JP2013129673A (ja) | 2006-04-21 | 2013-03-22 | 拮抗剤抗ｃｄ４０抗体薬学的組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8945564B2 (https=) |
| EP (1) | EP2019841A2 (https=) |
| JP (2) | JP5290152B2 (https=) |
| KR (1) | KR101317235B1 (https=) |
| CN (1) | CN101426817B (https=) |
| AR (1) | AR060487A1 (https=) |
| AU (1) | AU2007240507B2 (https=) |
| BR (1) | BRPI0710826A2 (https=) |
| CA (1) | CA2649907A1 (https=) |
| CR (1) | CR10379A (https=) |
| CU (1) | CU23856A3 (https=) |
| EA (1) | EA018301B1 (https=) |
| EC (1) | ECSP088903A (https=) |
| GE (1) | GEP20125628B (https=) |
| GT (1) | GT200700034A (https=) |
| HN (1) | HN2008001572A (https=) |
| IL (1) | IL194642A0 (https=) |
| MA (1) | MA30470B1 (https=) |
| ME (1) | MEP39508A (https=) |
| MX (1) | MX2008013508A (https=) |
| NI (1) | NI200800284A (https=) |
| NO (1) | NO20084796L (https=) |
| NZ (1) | NZ571757A (https=) |
| SA (1) | SA07280191B1 (https=) |
| SM (1) | SMP200800064B (https=) |
| SV (1) | SV2008003071A (https=) |
| TN (1) | TNSN08412A1 (https=) |
| TW (1) | TW200808349A (https=) |
| UA (1) | UA94264C2 (https=) |
| WO (1) | WO2007124299A2 (https=) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| AR060487A1 (es) * | 2006-04-21 | 2008-06-18 | Xoma Technology Ltd | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 |
| US7759304B2 (en) | 2006-06-21 | 2010-07-20 | Regents Of The University Of Colorado | Targeting complement factor H for treatment of diseases |
| PE20091174A1 (es) † | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2285409B1 (en) * | 2008-05-30 | 2016-04-20 | XBiotech, Inc | Il-1 alpha antibodies |
| CA2726087A1 (en) | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| TW201006485A (en) | 2008-06-03 | 2010-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CN102149825B (zh) | 2008-07-08 | 2015-07-22 | Abbvie公司 | 前列腺素e2双重可变结构域免疫球蛋白及其用途 |
| TWI541021B (zh) | 2009-03-05 | 2016-07-11 | 艾伯維有限公司 | Ｉｌ－１７結合蛋白 |
| WO2011003098A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| WO2011028811A2 (en) | 2009-09-01 | 2011-03-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| BR112012008833A2 (pt) | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| CA2795311A1 (en) | 2009-11-05 | 2011-05-12 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
| AU2013202276B2 (en) * | 2009-12-21 | 2016-03-24 | Genentech, Inc. | Antibody formulation |
| BR112012013093A2 (pt) * | 2009-12-21 | 2017-12-12 | Genentech Inc | ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável |
| HUE049849T2 (hu) * | 2010-03-31 | 2020-10-28 | Boehringer Ingelheim Int | Anti-CD40 antitestek |
| BR112012029067A2 (pt) | 2010-05-14 | 2019-09-24 | Univ Colorado Regents | grupos-alvo de receptor do complemento 2 (cr2) melhorados. |
| AR081246A1 (es) | 2010-05-14 | 2012-07-18 | Abbott Lab | Proteinas de union a il-1 |
| SG186397A1 (en) | 2010-06-22 | 2013-01-30 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3 |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP3252072A3 (en) | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| JP2013539364A (ja) | 2010-08-26 | 2013-10-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| EP2625292B1 (en) | 2010-10-07 | 2018-12-05 | The General Hospital Corporation | Biomarkers of cancer |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| PE20141060A1 (es) | 2010-12-21 | 2014-09-26 | Abbvie Inc | Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso |
| JP5458188B2 (ja) | 2011-02-17 | 2014-04-02 | 協和発酵キリン株式会社 | 抗ｃｄ４０抗体の高濃度製剤 |
| TR201909840T4 (tr) * | 2011-03-11 | 2019-07-22 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antikorları ve kullanımları. |
| HUE038848T2 (hu) | 2011-04-21 | 2018-11-28 | Bristol Myers Squibb Co | CD40-antagonista antitest polipeptidek |
| MX367097B (es) | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI-A4ß7. |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| HK1200322A1 (en) | 2011-10-24 | 2015-08-07 | Abbvie Inc. | Immunobinders directed against sclerostin |
| TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白 |
| HK1204990A1 (en) * | 2012-03-26 | 2015-12-11 | Sanofi | Stable igg4 binding agent formulations |
| EP4527855A3 (en) * | 2012-03-26 | 2025-06-11 | Sanofi | Stable igg4 based binding agent formulations |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| EP2859017B1 (en) | 2012-06-08 | 2019-02-20 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| UY34905A (es) | 2012-07-12 | 2014-01-31 | Abbvie Inc | Proteínas de unión a il-1 |
| JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| EP2890402B1 (en) | 2012-08-31 | 2019-04-17 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
| TW202037609A (zh) | 2012-11-01 | 2020-10-16 | 美商艾伯維有限公司 | 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途 |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| WO2014144280A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17 |
| US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
| US20160075766A1 (en) | 2013-05-21 | 2016-03-17 | Roche Diagnostics Operations, Inc. | Method for producing antibodies using ovine b-cells and uses thereof |
| HUE056580T2 (hu) | 2013-05-30 | 2022-02-28 | Kiniksa Pharmaceuticals Ltd | Onkosztatin-M-receptor antigénjét kötõ fehérjék |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| EP3055298B1 (en) | 2013-10-11 | 2020-04-29 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| CA2926089C (en) * | 2013-10-24 | 2022-08-30 | Medimmune, Llc | Stable, aqueous antibody formulations |
| EP3113796A1 (en) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| EP3146040B1 (en) * | 2014-05-19 | 2023-03-08 | F. Hoffmann-La Roche AG | Method for producing antibodies using ovine b-cells and uses thereof |
| EP3161159B1 (en) | 2014-06-25 | 2020-08-05 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| WO2016028810A1 (en) * | 2014-08-18 | 2016-02-25 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| CN116059378A (zh) | 2014-12-10 | 2023-05-05 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| WO2016115475A1 (en) * | 2015-01-18 | 2016-07-21 | Biogen Ma Inc. | Anti-cd40 antibody formulations |
| LT3297653T (lt) | 2015-05-22 | 2022-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais |
| CN107810198B (zh) * | 2015-05-29 | 2021-09-03 | 艾伯维公司 | 抗cd40抗体及其用途 |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| SG11201800864XA (en) | 2015-08-11 | 2018-03-28 | Univ Osaka | Antibody |
| CN107922501A (zh) * | 2015-09-01 | 2018-04-17 | 勃林格殷格翰国际有限公司 | 抗cd40抗体用于治疗狼疮性肾炎的用途 |
| BR112018004296B1 (pt) | 2015-09-04 | 2020-05-05 | Primatope Therapeutics Inc | anticorpos anti-cd40 humanizados e usos dos mesmos |
| BR112018006251A2 (pt) * | 2015-09-30 | 2018-10-16 | Janssen Biotech Inc | anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso |
| SG10202012778YA (en) * | 2015-12-18 | 2021-01-28 | Astellas Pharma Inc | Pharmaceutical composition comprising anti-human tslp receptor antibody |
| EA039944B1 (ru) * | 2016-01-27 | 2022-03-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Применение антител к cd40 для лечения волчаночного нефрита |
| KR102429230B1 (ko) * | 2016-02-20 | 2022-08-05 | 삼성전자주식회사 | 안테나 장치 및 안테나 장치를 포함하는 전자 장치 |
| JP7178906B2 (ja) | 2016-05-19 | 2022-11-28 | ザ ジェネラル ホスピタル コーポレイション | ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２ |
| TWI826351B (zh) * | 2016-05-31 | 2023-12-21 | 大陸商鴻運華寧（杭州）生物醫藥有限公司 | Ｒ抗體,其藥物組合物及其應用 |
| WO2017218698A1 (en) | 2016-06-15 | 2017-12-21 | Sutro Biopharma, Inc. | Antibodies with engineered ch2 domains, compositions thereof and methods of using the same |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| PT3528787T (pt) | 2016-10-21 | 2026-03-11 | Amgen Inc | Formulações farmacêuticas e métodos para produzir as mesmas |
| WO2018089688A1 (en) | 2016-11-09 | 2018-05-17 | Jinjun Shi | Restoration of tumor suppression using mrna-based delivery system |
| LT3541366T (lt) * | 2016-11-21 | 2025-03-10 | Amylyx Pharmaceuticals, Inc. | Eksendino (9-39) buferiniai preparatai |
| MX2019012255A (es) * | 2017-04-11 | 2019-12-05 | Kiniksa Pharmaceuticals Ltd | Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr). |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| AU2018322475A1 (en) * | 2017-08-22 | 2020-03-05 | Biogen Ma Inc. | Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies |
| GB201717966D0 (en) | 2017-10-31 | 2017-12-13 | Xenikos Bv | Immunotoxins, formulations thereof and their use in medicine |
| EP4317972A3 (en) | 2018-02-06 | 2024-03-13 | The General Hospital Corporation | Repeat rna as biomarkers of tumor immune response |
| JP2021513367A (ja) * | 2018-02-12 | 2021-05-27 | ダイアベーツ−フリー， インコーポレイテッド | 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2020014471A1 (en) | 2018-07-11 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of agents across the blood-brain barrier |
| WO2020081408A1 (en) * | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| WO2020193718A1 (en) * | 2019-03-27 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with cd40 activating properties |
| US20200318200A1 (en) | 2019-04-02 | 2020-10-08 | The Brigham And Women's Hospital, Inc. | Methods for Identifying Progression of a Primary Melanoma |
| JPWO2020213568A1 (https=) * | 2019-04-18 | 2020-10-22 | ||
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CN115279400B (zh) | 2020-01-10 | 2026-04-28 | 布里格姆妇女医院 | 用于跨血脑屏障递送免疫治疗剂以治疗脑癌的方法和组合物 |
| BR112022013730A2 (pt) * | 2020-01-13 | 2022-10-11 | Aptevo Res & Development Llc | Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas |
| JP2023514721A (ja) * | 2020-02-24 | 2023-04-07 | メディミューン，エルエルシー | 抗内皮リパーゼ抗体の製剤 |
| US20230095053A1 (en) | 2020-03-03 | 2023-03-30 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| KR20230131212A (ko) * | 2021-01-14 | 2023-09-12 | 한올바이오파마주식회사 | 안정화제를 사용하지 않고도 안정한, 탄파너셉트를포함하는 안과용 조성물 |
| AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| US12234294B2 (en) * | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| US20230279135A1 (en) * | 2021-11-05 | 2023-09-07 | Kiniksa Pharmaceuticals, Ltd. | Pharmaceutical compositions of humanized anti-cd40 antibodies |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| TW202432601A (zh) | 2022-11-07 | 2024-08-16 | 美商上游生物公司 | 包含抗人類ｔｓｌｐ受體抗體之醫藥組成物及其使用方法 |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2026043823A2 (en) | 2024-08-19 | 2026-02-26 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof |
| WO2026080697A1 (en) | 2024-10-09 | 2026-04-16 | Sutro Biopharma, Inc. | Antibody conjugates with high payload to antibody ratios, compositions comprising the same, and methods of their use |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| NZ273504A (en) | 1993-10-01 | 1997-12-19 | Immunex Corp | Monoclonal antibodies (moabs) that specifically bind human cd40 molecules and cd40 ligand binding |
| ES2222463T3 (es) | 1993-12-23 | 2005-02-01 | Immunex Corporation | Uso de anticuerpos monoclonales o ligandos oligomericos solubles en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos neoplasicos. |
| CA2184356A1 (en) | 1994-03-03 | 1995-09-08 | Russell P. Rother | Terminal complement inhibitor fusion genes and proteins |
| GB9425060D0 (en) | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| CN1261285A (zh) | 1997-06-20 | 2000-07-26 | 拜奥根有限公司 | 治疗性蛋白抑制剂综合症的cd154阻断治疗 |
| AU2444899A (en) * | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| JP2003508016A (ja) | 1999-04-16 | 2003-03-04 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| CZ20021186A3 (cs) * | 1999-10-04 | 2002-11-13 | Chiron Corporation | Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| AU1590201A (en) | 1999-11-09 | 2001-06-06 | Chiron Corporation | Compositions and methods for treating autoimmune diseases and transplant rejections |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| AU2001259215A1 (en) | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| AU6461201A (en) | 2000-07-12 | 2002-01-21 | Idec Pharma Corp | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| JP2004508420A (ja) | 2000-09-18 | 2004-03-18 | アイデック ファーマスーティカルズ コーポレイション | Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法 |
| EP1322383B9 (en) | 2000-10-02 | 2006-09-06 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| CN100574803C (zh) | 2001-01-31 | 2009-12-30 | 拜奥根Idec公司 | 免疫调节抗体在治疗肿瘤性疾病中的用途 |
| IL157946A0 (en) | 2001-04-02 | 2004-03-28 | Genentech Inc | Combination therapy |
| CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| WO2003029296A1 (en) | 2001-10-02 | 2003-04-10 | Chiron Corporation | Human anti-cd40 antibodies |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| AU2002346581A1 (en) | 2001-11-26 | 2003-06-10 | Chiron Corporation | Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment |
| SI1478394T1 (sl) * | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20040022792A1 (en) * | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
| DE602004019761D1 (de) | 2003-01-08 | 2009-04-16 | Novartis Vaccines & Diagnostic | Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante |
| MXPA05010555A (es) * | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| CN1816356A (zh) | 2003-05-14 | 2006-08-09 | 免疫原公司 | 药物缀合物组合物 |
| HUE026793T2 (en) * | 2003-10-01 | 2016-07-28 | Kyowa Hakko Kirin Co Ltd | A method for stabilizing an antibody and a stabilized solution-type antibody preparation |
| KR101128777B1 (ko) | 2003-11-04 | 2012-04-13 | 조마 테크놀로지 리미티드 | 다발성 골수종을 치료하기 위한 길항제 항-ｃｄ４０단클론성 항체의 용도 |
| PL1680141T3 (pl) | 2003-11-04 | 2011-04-29 | Novartis Vaccines & Diagnostics Inc | Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40 |
| US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| SI1682177T1 (sl) | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostic | Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije |
| WO2005044307A2 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Methods of therapy for b cell-related cancers |
| ATE447412T1 (de) | 2003-11-04 | 2009-11-15 | Novartis Vaccines & Diagnostic | Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren |
| DE10355251A1 (de) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
| EP1712240B1 (en) * | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
| CA2567309A1 (en) * | 2004-06-01 | 2005-12-15 | Ares Trading S.A. | Method of stabilizing proteins |
| DE102004028815A1 (de) | 2004-06-15 | 2006-01-12 | Siemens Ag | Verfahren zur Ressourcen-Reservierung für ein Inter-Domain-Routing mit Dienstgütemerkmalen |
| TW200621282A (en) * | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| US20080057070A1 (en) | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| AU2006247067B2 (en) | 2005-05-18 | 2012-06-07 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling |
| JP5421590B2 (ja) | 2005-05-18 | 2014-02-19 | ノバルティス アーゲー | 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法 |
| EP1888637A2 (en) * | 2005-05-19 | 2008-02-20 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| CA2638811A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| AR060487A1 (es) * | 2006-04-21 | 2008-06-18 | Xoma Technology Ltd | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 |
-
2007
- 2007-04-17 AR ARP070101626 patent/AR060487A1/es not_active Application Discontinuation
- 2007-04-17 MX MX2008013508A patent/MX2008013508A/es active IP Right Grant
- 2007-04-17 NZ NZ571757A patent/NZ571757A/en not_active IP Right Cessation
- 2007-04-17 BR BRPI0710826-5A patent/BRPI0710826A2/pt not_active IP Right Cessation
- 2007-04-17 UA UAA200813220A patent/UA94264C2/ru unknown
- 2007-04-17 US US12/297,382 patent/US8945564B2/en not_active Expired - Fee Related
- 2007-04-17 EP EP07760754A patent/EP2019841A2/en not_active Withdrawn
- 2007-04-17 JP JP2009506711A patent/JP5290152B2/ja not_active Expired - Fee Related
- 2007-04-17 CN CN2007800139737A patent/CN101426817B/zh not_active Expired - Fee Related
- 2007-04-17 SM SM200800064T patent/SMP200800064B/it unknown
- 2007-04-17 AU AU2007240507A patent/AU2007240507B2/en not_active Ceased
- 2007-04-17 GE GEAP2007010985 patent/GEP20125628B/en unknown
- 2007-04-17 KR KR1020087025721A patent/KR101317235B1/ko not_active Expired - Fee Related
- 2007-04-17 WO PCT/US2007/066757 patent/WO2007124299A2/en not_active Ceased
- 2007-04-17 EA EA200802135A patent/EA018301B1/ru not_active IP Right Cessation
- 2007-04-17 ME MEP-395/08A patent/MEP39508A/xx unknown
- 2007-04-17 CA CA002649907A patent/CA2649907A1/en not_active Abandoned
- 2007-04-18 SA SA7280191A patent/SA07280191B1/ar unknown
- 2007-04-18 GT GT200700034A patent/GT200700034A/es unknown
- 2007-04-18 TW TW96113569A patent/TW200808349A/zh unknown
-
2008
- 2008-10-07 IL IL194642A patent/IL194642A0/en unknown
- 2008-10-17 TN TNP2008000412A patent/TNSN08412A1/en unknown
- 2008-10-20 CR CR10379A patent/CR10379A/es not_active Application Discontinuation
- 2008-10-21 CU CU2008000196A patent/CU23856A3/es not_active IP Right Cessation
- 2008-10-21 SV SV2008003071A patent/SV2008003071A/es unknown
- 2008-10-21 NI NI200800284A patent/NI200800284A/es unknown
- 2008-10-21 HN HN2008001572A patent/HN2008001572A/es unknown
- 2008-11-10 MA MA31374A patent/MA30470B1/fr unknown
- 2008-11-13 NO NO20084796A patent/NO20084796L/no not_active Application Discontinuation
- 2008-11-21 EC ECSP088903 patent/ECSP088903A/es unknown
-
2013
- 2013-03-22 JP JP2013059446A patent/JP2013129673A/ja active Pending
-
2014
- 2014-12-18 US US14/575,182 patent/US20150110783A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009534401A5 (https=) | ||
| US10822425B2 (en) | Single variable domain antibodies against OX40L, constructs and therapeutic use | |
| JP2007510666A5 (https=) | ||
| RU2559525C2 (ru) | Белки, связывающие простагландин е2, и их применение | |
| JP5214252B2 (ja) | ヒト化ｌ２４３抗体 | |
| JP5677972B2 (ja) | ヒト血清アルブミンリンカーおよびそのコンジュゲート | |
| US20230338588A1 (en) | Granzyme B Directed Imaging and Therapy | |
| TWI392503B (zh) | 抗－ｃｄ７９ｂ抗體及免疫共軛物及使用方法 | |
| JP2008516970A5 (https=) | ||
| JP2023519890A (ja) | 免疫状態の処置のためのｍｋ２経路阻害剤の経口組成物 | |
| CN102369218A (zh) | 抗-FcRH5抗体和免疫缀合物以及应用方法 | |
| JP2012139224A5 (https=) | ||
| JP2008525449A (ja) | Ｂ細胞疾患の併用療法 | |
| KR20180008921A (ko) | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| TW201038286A (en) | Anti-FcRH5 antibodies and immunoconjugates and methods of use | |
| JP2015504306A5 (https=) | ||
| TW201425336A (zh) | Ｂｃｍａ抗原結合蛋白質 | |
| TW200848429A (en) | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders | |
| BR112013033916B1 (pt) | Uso de um anticorpo específico para cd19 | |
| JP2019523764A5 (https=) | ||
| KR20240132016A (ko) | 그랜자임 b에 특이적인 화합물 및 그의 용도 | |
| TW202024088A (zh) | 磷酸肌醇3激酶(pi3k)抑制劑之結晶形式 |